Overall, the cellular immunity results indicate that HD patients are able to mount and maintain a robust cellular immune response over time, while HV individuals decrease their ability to secrete both IFN-γ and IL-2 after a booster dose. The gene discussed is IFNG; the disease is Huntington disease.